---
figid: PMC6594147__BJH-185-25-g001
figtitle: Dysregulated immune response in the primary mediastinal B‐cell lymphoma
  (PMBCL) tumour microenvironment
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6594147
filename: BJH-185-25-g001.jpg
figlink: /pmc/articles/PMC6594147/figure/bjh15778-fig-0001/
number: F1
caption: Dysregulated immune response in the primary mediastinal B‐cell lymphoma (PMBCL)
  tumour microenvironment. Activating (red) genetic lesions/copy number gains and
  inactivating (blue) gene mutations in components of the JAK‐STAT signalling pathway
  diminish tumour immunogenicity via upregulation of programmed death ligands (PDLs)
  and C‐C motif chemokine ligand 17 (CCL17). Microdeletions in CD58 and mutations/structural
  rearrangements in class II major histocompatibility complex transactivator (CIITA)
  impair tumour antigenicity via downregulation of conjugate formation and major histocompatibility
  complex (MHC) class II, respectively. These immune escape strategies lead to T‐cell
  exhaustion, activation of suppressive T‐regulatory cells (Treg) and crippled immune
  surveillance. The impact of genetic aberrations in components of the nuclear factor
  kappa B (NF‐ĸB) signalling pathway on the PMBCL tumour microenvironment is not known.
papertitle: 'Biology and therapy of primary mediastinal B‐cell lymphoma: current status
  and future directions.'
reftext: Charlotte Lees, et al. Br J Haematol. 2019 Apr;185(1):25-41.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8696958
figid_alias: PMC6594147__F1
figtype: Figure
redirect_from: /figures/PMC6594147__F1
ndex: 4521e290-df14-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6594147__BJH-185-25-g001.html
  '@type': Dataset
  description: Dysregulated immune response in the primary mediastinal B‐cell lymphoma
    (PMBCL) tumour microenvironment. Activating (red) genetic lesions/copy number
    gains and inactivating (blue) gene mutations in components of the JAK‐STAT signalling
    pathway diminish tumour immunogenicity via upregulation of programmed death ligands
    (PDLs) and C‐C motif chemokine ligand 17 (CCL17). Microdeletions in CD58 and mutations/structural
    rearrangements in class II major histocompatibility complex transactivator (CIITA)
    impair tumour antigenicity via downregulation of conjugate formation and major
    histocompatibility complex (MHC) class II, respectively. These immune escape strategies
    lead to T‐cell exhaustion, activation of suppressive T‐regulatory cells (Treg)
    and crippled immune surveillance. The impact of genetic aberrations in components
    of the nuclear factor kappa B (NF‐ĸB) signalling pathway on the PMBCL tumour microenvironment
    is not known.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NFKB1
  - IL4
  - IL13
  - TNF
  - JAK2
  - SOCS1
  - CIITA
  - AGFG1
  - RIPK1
  - DCAF1
  - RPAIN
  - TRAF1
  - TRAF2
  - TRAF3
  - TRAF4
  - TRAF5
  - TRAF6
  - TRAF7
  - TNFAIP3
  - IGKV1-27
  - STAT6
  - NFKBIA
  - NFKBIE
  - FKBP4
  - GTF2H4
  - NFKB2
  - PMPCB
  - PSIP1
  - H3P42
  - RELB
  - CCL17
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - REL
  - HLA-DRA
  - HLA-DRB1
  - HLA-DRB3
  - HLA-DRB4
  - HLA-DRB5
  - CD58
  - CCR4
  - CNOT6
  - CD274
  - PDCD1LG2
  - CD4
  - FOXP3
  - IL2RA
  - ISG20
  - CD2
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CD8A
  - CD8B
  - IL4R
  - HLA-C
  - MPEG1
  - PDCD1
  - RPL17
  - SNCA
  - SPATA2
  - RPL17-C18orf32
  - DCLK1
  - ADGRL1
  - CLU
  - AKR1C4
  - GZMB
  - POLR3K
  - Rheumatoid arthritis
---
